Please login to the form below

Not currently logged in
Email:
Password:

Akcea Therapeutics

This page shows the latest Akcea Therapeutics news and features for those working in and with pharma, biotech and healthcare.

Novartis highlights emerging assets and late-stage pipeline at R&D day

Novartis highlights emerging assets and late-stage pipeline at R&D day

TQJ230, an antisense oligonucleotide it licensed from Akcea Therapeutics in February, which reduces Lp(a), a currently untreatable risk factor for cardiovascular disease – an outcomes trial of over 7, 500 patients

Latest news

More from news
Approximately 2 fully matching, plus 6 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
W2O Group

W2O Group is an integrated marketing agency with expertise in brand and digital strategy, creative development and communications services. We...

Latest intelligence

Mistrust in medical research: a patient perspective
The recent development of several COVID-19 vaccines has placed medical research firmly in the spotlight, highlighting public confusion and misinformation about clinical trials. Patient advocate, Trishna Bharadia reveals what the...
Real-world evidence: breaking boundaries in rare disease
Generating data for drug launches is a challenging process. In rare diseases, with small patient populations and high unmet need, evidence generation is even more complex. Consultant Sarah Poole and...
The heavy toll of COVID-19 on cancer patients
We all know that finding and treating cancer early saves lives. During the COVID-19 pandemic, oncology treatments paused while cancer continued to spread. So, what has been the impact of...

Infographics